Healthcare [ 7/13 ] | Biotechnology [ 61/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 22, 24 | -3.01 Decreased by -35.59% | -2.65 Decreased by -13.58% |
| Nov 2, 23 | -3.16 Decreased by -32.77% | -2.74 Decreased by -15.33% |
| Aug 3, 23 | -2.75 Decreased by -26.73% | -2.78 Increased by +1.08% |
| May 4, 23 | -2.8 Decreased by -43.59% | -2.76 Decreased by -1.45% |
| Feb 23, 23 | -2.22 Decreased by -136.17% | -2.25 Increased by +1.33% |
| Nov 3, 22 | -2.38 Decreased by -38.37% | -2.13 Decreased by -11.74% |
| Aug 8, 22 | -2.17 Decreased by -85.47% | -2.09 Decreased by -3.83% |
| May 5, 22 | -1.95 Decreased by -82.24% | -2.11 Increased by +7.58% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 0 Decreased by -100% | -113.82 M Decreased by -49.35% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0 Decreased by -100% | -119.12 M Decreased by -72.52% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by -100% | -103.16 M Decreased by -58.85% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 654 K Increased by +N/A% | -86.08 M Decreased by -49.43% | Decreased by -13.16 K% Decreased by N/A% |
| Dec 31, 22 | 5.28 M Decreased by -85.72% | -76.21 M Decreased by -172.58% | Decreased by -1.44 K% Decreased by -1.81 K% |
| Sep 30, 22 | 81 K Increased by +N/A% | -69.05 M Decreased by -35.57% | Decreased by -85.24 K% Decreased by N/A% |
| Jun 30, 22 | 5.28 M Increased by +N/A% | -64.94 M Decreased by -88.7% | Decreased by -1.23 K% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -57.6 M Decreased by -88.89% | Decreased by N/A% Decreased by N/A% |
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.